Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).

Juan P HorcajadaRebeca AldonzaMónica RealSilvia Castañeda-EspinosaElena SendraJoan Gomez-JunyentInmaculada López-MontesinosSilvia Gómez-ZorrillaSilvia BriansóMontserrat Duran-TabernaAndrés FernándezCristina TarragóTeresa Auguet-Quintillánull nullnull null

Published in: Pneumonia (Nathan Qld.) (2024)

Favipiravir administered for ten days to patients with COVID-19 and pneumonia did not improve outcomes compared with placebo. Although this is an underpowered negative study, efficacy results align with other randomized trials. However, in the present study, the non-serious adverse events were more frequent in the favipiravir group.

Keyphrases

double blind
coronavirus disease
sars cov
clinical trial
randomized controlled trial
metabolic syndrome
phase iii
respiratory failure